Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.12 - $1.57 $1,120 - $1,570
-1,000 Reduced 22.73%
3,400 $5,000
Q4 2023

Feb 14, 2024

SELL
$0.72 - $1.56 $3,024 - $6,552
-4,200 Reduced 48.84%
4,400 $6,000
Q3 2023

Nov 14, 2023

BUY
$1.07 - $1.39 $1,177 - $1,529
1,100 Added 14.67%
8,600 $9,000
Q2 2023

Aug 14, 2023

SELL
$1.12 - $1.82 $2,800 - $4,550
-2,500 Reduced 25.0%
7,500 $9,000
Q1 2023

May 15, 2023

SELL
$1.25 - $2.0 $1,500 - $2,400
-1,200 Reduced 10.71%
10,000 $13,000
Q4 2022

Feb 14, 2023

BUY
$0.67 - $11.9 $402 - $7,140
600 Added 5.66%
11,200 $16,000
Q3 2022

Nov 14, 2022

SELL
$1.1 - $12.2 $8,470 - $93,940
-7,700 Reduced 42.08%
10,600 $13,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.84B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.